From L-R: Marc Tessier-Lavigne, Bob Nelsen, David Baker and Vik Bajaj
April 23, 2024 07:00 AM EDTUpdated 11:05 AM
Startups
Deals
R&D

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

Andrew Dunn

Senior Biopharma Correspondent

Ryan Cross

Senior Science Correspondent

A star-stud­ded mix of ven­ture cap­i­tal­ists and sci­en­tists, backed by more than a bil­lion dol­lars, is launch­ing an am­bi­tious biotech that aims to rein­vent drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times